Immunophenotype Expression Change From CD52+ to CD52- on Erythrodermic Peripheral T-cell Lymphoma, Not Otherwise Specified After Treatment With Alemtuzumab

Am J Dermatopathol. 2018 Jul;40(7):547-550. doi: 10.1097/DAD.0000000000001000.
No abstract available

Publication types

  • Comparative Study
  • Letter

MeSH terms

  • Alemtuzumab / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use
  • Biopsy, Needle
  • CD52 Antigen / genetics*
  • CD52 Antigen / metabolism
  • Female
  • Follow-Up Studies
  • Gene Expression Regulation*
  • Humans
  • Immunohistochemistry
  • Immunophenotyping / methods
  • Lymphoma, T-Cell, Peripheral / drug therapy*
  • Lymphoma, T-Cell, Peripheral / genetics
  • Lymphoma, T-Cell, Peripheral / pathology*
  • Male
  • Molecular Targeted Therapy / methods
  • Risk Assessment
  • Skin Neoplasms / drug therapy
  • Skin Neoplasms / genetics*
  • Skin Neoplasms / pathology
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • CD52 Antigen
  • Alemtuzumab